OS THERAPIES INCORPORATED Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
OS THERAPIES INCORPORATED (OSTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.47 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- OS THERAPIES INCORPORATED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.47.
- OS THERAPIES INCORPORATED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.80, a 3.23% decline from fiscal 2024.
- OS THERAPIES INCORPORATED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.86.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|
| 2026-06-30 | $1.47 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $1.47 10-Q · filed 2026-05-18 | ||
| 2025-12-31 | $1.80 10-K · filed 2026-03-31 | ||
| 2024-12-31 | $1.86 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |